2. Immunology/Inflammation
  3. Interleukin Related
  4. Suplatast (Tosilate)

Suplatast (Tosilate)  (Synonyms: IPD 1151T)

Cat. No.: HY-17002 Purity: 98.33%
SDS COA Handling Instructions

Molarity Calculator

Suplatast Tosilate (IPD 1151T) is an orally active Th2 cytokine inhibitor which can inhibit both IL-4 and IL-5 production from Th2 cells and suppress IgE synthesis. Suplatast Tosilate is an anti-allergic agent. Suplatast Tosilate has antiasthmatic, anti-inflammatory and antifibrotic activity.

For research use only. We do not sell to patients.

Suplatast (Tosilate) Chemical Structure

Suplatast (Tosilate) Chemical Structure

CAS No. : 94055-76-2

Size Price Stock Quantity
Free Sample (0.1 - 0.5 mg)   Apply Now  
Solid + Solvent (Highly Recommended)
10  mM * 1 mL in DMSO
ready for reconstitution
 USD 55 In-stock
Solution
10  mM * 1 mL in DMSO USD 55 In-stock
Solid
50 mg USD 50 In-stock
100 mg USD 85 In-stock
500 mg USD 298 In-stock
1 g   Get quote  
5 g   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 1 publication(s) in Google Scholar

Suplatast (Tosilate) Related Antibodies

Top Publications Citing Use of Products

1 Publications Citing Use of MCE Suplatast (Tosilate)

View All Interleukin Related Isoform Specific Products:

View All Isoforms
IL-1 IL-2 IL-3 IL-4 IL-5 IL-6 IL-8 IL-10 IL-12 IL-13 IL-15 IL-17 IL-23 IL-7 IL-33 IL-22

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

Suplatast Tosilate (IPD 1151T) is an orally active Th2 cytokine inhibitor which can inhibit both IL-4 and IL-5 production from Th2 cells and suppress IgE synthesis. Suplatast Tosilate is an anti-allergic agent. Suplatast Tosilate has antiasthmatic, anti-inflammatory and antifibrotic activity[1][2][3][4].

IC50 & Target[1]

IL-4

 

IL-2

 

IL-5

 

IL-13

 

In Vitro

IPD-1151T (1-10 μM; 10 d) induces a concentration-dependent suppression of purified allergen (Cry j 1)-dependent IgE synthesis in autologous B cell cultures mediated by SN-4, without significantly affecting the IgG synthesis[1].
IPD-1151T (1-10 μM; 24 h) clearly depresses phytohemagglutinin (PHA)-induced expression of IL-4 mRNA in normal peripheral blood mononuclear cells (PBMC)[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Suplatast (Tosilate) Related Antibodies
In Vivo

Suplatast Tosilate (100 mg/kg; once daily for 21 d) inhibits the production of Th2 cytokines, which inhibits eosinophil infiltration into the murine airway, IgE synthesis, and development of BHR, in a murine model of asthma[2].
Suplatast Tosilate (100 μg/kg; once daily for 14 d) strongly suppresses immunoglobulin E contents in serum[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Female BALB/c mice (6-8 weeks old) are immunized with ovalbumin[3]
Dosage: 100 mg/kg
Administration: P.o. once a day for 21 days
Result: Reduced the number of total cells and eosinophils.
Almost completely inhibited the development of antigen-induced bronchial hyperresponsiveness (BHR).
Decreased the levels of IL-4, IL-5 and IL-13.
Molecular Weight

499.64

Formula

C23H33NO7S2
CAS No.
Appearance

Solid

Color

White to off-white

SMILES

C[S+](C)CCC(NC1=CC=C(C=C1)OCC(COCC)O)=O.CC2=CC=C(C=C2)S(=O)([O-])=O
Shipping

Room temperature in continental US; may vary elsewhere.
Storage

4°C, sealed storage, away from moisture

*In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

Solvent & Solubility
In Vitro: 

H2O : ≥ 100 mg/mL (200.14 mM)

DMSO : ≥ 33 mg/mL (66.05 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

*"≥" means soluble, but saturation unknown.

Preparing
Stock Solutions
Concentration Solvent Mass 1 mg 5 mg 10 mg
1 mM 2.0014 mL 10.0072 mL 20.0144 mL
5 mM 0.4003 mL 2.0014 mL 4.0029 mL
View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

  • Molarity Calculator

  • Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass
=
Concentration
×
Volume
×
Molecular Weight *

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start)

C1

×
Volume (start)

V1

=
Concentration (final)

C2

×
Volume (final)

V2

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

  • Protocol 1

    Add each solvent one by one:  10% DMSO    40% PEG300    5% Tween-80    45% Saline

    Solubility: ≥ 2.5 mg/mL (5.00 mM); Clear solution

    This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

    Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

    Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
  • Protocol 2

    Add each solvent one by one:  10% DMSO    90% (20% SBE-β-CD in Saline)

    Solubility: ≥ 2.5 mg/mL (5.00 mM); Clear solution

    This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

    Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

    Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

g

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Calculation results:
Working solution concentration: mg/mL
This product has good water solubility, please refer to the measured solubility data in water/PBS/Saline for details.
The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only.If necessary, please contact MedChemExpress (MCE).
Purity & Documentation

Purity: 98.33%

SDS (393 KB)

COA (250 KB) LCMS (269 KB)

Handling Instructions (2659 KB)
References

Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Optional Solvent Concentration Solvent Mass 1 mg 5 mg 10 mg 25 mg
DMSO / H2O 1 mM 2.0014 mL 10.0072 mL 20.0144 mL 50.0360 mL
5 mM 0.4003 mL 2.0014 mL 4.0029 mL 10.0072 mL
10 mM 0.2001 mL 1.0007 mL 2.0014 mL 5.0036 mL
15 mM 0.1334 mL 0.6671 mL 1.3343 mL 3.3357 mL
20 mM 0.1001 mL 0.5004 mL 1.0007 mL 2.5018 mL
25 mM 0.0801 mL 0.4003 mL 0.8006 mL 2.0014 mL
30 mM 0.0667 mL 0.3336 mL 0.6671 mL 1.6679 mL
40 mM 0.0500 mL 0.2502 mL 0.5004 mL 1.2509 mL
50 mM 0.0400 mL 0.2001 mL 0.4003 mL 1.0007 mL
60 mM 0.0334 mL 0.1668 mL 0.3336 mL 0.8339 mL
H2O 80 mM 0.0250 mL 0.1251 mL 0.2502 mL 0.6255 mL
100 mM 0.0200 mL 0.1001 mL 0.2001 mL 0.5004 mL

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

Suplatast (Tosilate) Related Classifications

Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Suplatast (Tosilate)94055-76-2IPD 1151TInterleukin RelatedILInhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

  

Salutation

Applicant Name *

 

Email Address *

Phone Number *

 

Organization Name *

Department *

 

Requested quantity *

Country or Region *

      

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
Suplatast (Tosilate)
Cat. No.:
HY-17002
Quantity:
MCE Japan Authorized Agent:

Customer Review

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Product Name

  

Lot #

Applicant Name *

 

Email Address *

Phone Number

 

Department *

Organization Name *

 

Country or Region *

Remarks

SAFETY DATA SHEET (SDS)

English - EN (393 KB) Français - FR (393 KB) Deutsch - DE (393 KB) Norwegian - NO (393 KB) Español - ES (393 KB) Swedish - SV (393 KB)

Request for HNMR Report

We have received your request and will respond to you as soon as possible.